1	Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19
2	vaccine in adults: data from a randomised, double-blind, placebo-
3	controlled, single-dose, phase 3 trial in Russia
4	
5	Dmitry Lioznov ^{1,2} , Irina Amosova ¹ , Savely A. Sheetikov ³ , Ksenia V. Zornikova ³ , Yana Serdyuk ³ ,
6	Grigory A. Efimov ³ , Mikhail Tsyferov ⁴ , Mikhail Khmelevskii ⁴ , Andrei Afanasiev ⁴ , Nadezhda
7	Khomyakova ⁴ , Dmitry Zubkov ⁴ , Anton Tikhonov ⁴ , Tao Zhu ⁵ , Luis Barreto ⁵ , Vitalina Dzutseva ^{4,6*}
8	
9	¹ Smorodintsev Research Institute of Influenza, St Petersburg, Russia
10	² Department of Infectious Diseases and Epidemiology, First Pavlov State Medical University, St.
11	Petersburg, Russia
12	³ National Research Center for Hematology, Moscow, Russia
13	⁴ NPO Petrovax Pharm LLC, Moscow, Russia
14	⁵ CanSino Biologics Inc., Tianjin, China
15	⁶ Novosibirsk State University, Medical School, Novosibirsk, Russia
16	* Corresponding author
17	E-mail: DzutsevaVV@petrovax.ru (VD)
18	

19 Short title: COVID-19 vaccination Ad5-nCoV in Russian adults

20 ABSTRACT

21 **Background:** To determine the immunogenicity, efficacy, reactogenicity, and safety of a single dose of recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV, 5×10^{10} viral particles 22 23 per 0.5 mL dose), we conducted a single-dose, randomised, double-blind, placebo-controlled, parallel 24 group (3:1 Ad5-nCoV:placebo), phase 3 trial (Prometheus). 25 Methods: From 11-September-2020 to 05-May-2021, across six sites in the Russian Federation, 496 26 participants were injected with either placebo or Ad5-nCoV expressing the full-length spike (S) 27 protein from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 28 **Results:** Seroconversion (the primary endpoint) rates of 78.5% (95% CI: 73.9; 82.6) against receptor 29 binding domain (RBD), 90.6% (95% CI: 87.2; 93.4) against S protein and 59% (95% CI: 53.3; 64.6) 30 against neutralising SARS-CoV2 antibodies 28 days post-vaccination. Geometric mean titres 31 (GMTs) were also elevated for antibodies against the RBD (405.32 [95% CI: 361.58; 454.46]) and S 32 protein (678.86 [95% CI: 607.44; 754.40]) compared to the GMT of neutralising antibodies against 33 SARS-CoV-2 (16.73 [95% CI: 15.36; 18.22]). Using an IFN-γ ELISpot assay after stimulating the 34 cells with full-length S protein we showed that the Ad5-nCoV vaccine induced the most robust 35 cellular immune response on Days 14 and 28. Up to Day 28, the primary and all secondary endpoints 36 of the Ad5-nCoV vaccine were statistically superior to the placebo (p<0.001). Systemic reactions 37 were reported in 113 of 496 (22.8%) participants (Ad5-nCoV, 26.9%; Placebo, 10.5%), and local 38 reactions were reported in 108 (21.8%) participants (Ad5-nCoV, 28.5%; Placebo, 1.6%). These were 39 generally mild and resolved within 7 days after vaccination. Of the six serious adverse events 40 reported, none of the events were vaccine related. There were no deaths or premature withdrawals.

41 Conclusion: A single-dose of Ad5-nCoV vaccine induced a marked specific humoral and cellular
42 immune response with a favourable safety profile.

43 **Trial Registration:** ClinicalTrials.gov: NCT04540419

44 **INTRODUCTION**

45 The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 46 (SARS-CoV-2) has resulted in morbidity and mortality unseen since the Spanish flu outbreak more 47 than a century ago [1]. Quarantine measures, a traditional public health method of infection control, 48 have been only partially effective in the face of this highly transmissible virus [2]. Vaccination has 49 the potential to reduce disease severity and transmission but requires expedited development and 50 global administration. In response to this enormous task, many potential vaccine candidates are in 51 development, with several now approved for full or limited use being actively administered [3–6]. A 52 range of technologies have been used in the development of SARS-CoV-2 vaccines, including 53 replicating or non-replicating viral vectors, inactivated viruses and mRNA, DNA or autologous cell-54 based vaccines. It is not currently known which approach provides the most effective immunity for 55 different recipient risk groups with an acceptable safety profile, all at acceptable levels of cost with 56 ease of manufacturing and distribution [7].

57 A candidate COVID-19 vaccine that initially showed a capacity to induce a significant antibody and 58 cellular immune response is the adenovirus type 5 (Ad5)-nCoV vaccine developed by CanSino 59 Biologics Inc., Tianjin, and the Beijing Institute of Biotechnology, People's Republic of China. It 60 consists of a replication-defective Ad5 vector expressing the SARS-CoV-2 spike (S) protein, 61 including its receptor-binding domain (RBD). This protein serves as the main antigen in SARS-CoV-62 2 vaccines [8]. The Ad5-nCoV vaccine was one of the first to enter phase 1 and 2 clinical trials in 63 China, 2 months after the identification of the virus genotype and the results showed the vaccine to 64 be safe and immunogenic after a single dose [9, 10]. Its potential advantages are single-dose 65 immunization and its proven technology, both of which were used previously for the Ebola vaccine 66 (Ad5-EBOV), and its stability that permits it to be stored in a standard refrigerator at $2-8^{\circ}$ C, 67 enabling the ease of worldwide distribution.

68 A collaborative development project between CanSino Biologics and the Russian pharmaceutical

- 69 company NPO Petrovax Pharm LLC provided the basis for a new phase 3 study, Prometheus Rus.
- 70 This multicentre, randomised, double-blind, placebo-controlled clinical trial examines the
- 71 immunogenicity, reactogenicity, efficacy and safety of the Ad5-nCoV COVID-19 vaccine compared
- 72 with placebo, in a mostly white, Russian population. The study population was recruited at centres in
- the western part of the Russian federation (Moscow, St. Petersburg and Yaroslavl) and therefore
- 74 provides the first clinical data available for Ad5-nCoV in a white European population; previously
- published data were based on the phase 1 and 2 clinical trials conducted in China. We present the
- 76 final analysis of the 496 participants in this phase 3 trial.

77 MATERIALS AND METHODS

- 78 The protocol for this trial and supporting CONSORT checklist are available as supporting
- 79 information; see S1 Protocol and S1 Checklist, respectively.

80 Ethical Conduct of the Study

- 81 The study proceeded in accordance with the principles of the Declaration of Helsinki and Good
- 82 Clinical Practice. The trial protocol was reviewed and approved by the Independent Ethics
- 83 Committees of the involved sites and the Ethics Council of the Ministry of Health of the Russian
- 84 Federation. The study design and methodology have been developed in line with the FDA [11], EMA
- 85 [12] and EAEU [13] guidelines, as well as the regulatory documents of the Russian Federation [14].
- 86 The trial is registered with ClinicalTrials.gov, NCT04540419 [15].
- 87 To be included, participants needed to be able to understand the content of the informed consent
- 88 documents and be willing to sign the informed consent form. Written informed consent was obtained
- 89 from each participant before eligibility screening.

90 Study Design and Participants

- 91 Prometheus is a multicentre, randomised, double-blind, placebo-controlled, clinical trial being
- 92 conducted in six centres in the Russian Federation. The study seeks to evaluate the immunogenicity,

93 efficacy, reactogenicity and safety of a single dose of the Ad5-nCoV COVID-19 vaccine compared

- 94 with placebo in adults up to 6 months after vaccination. Competitive recruitment of the planned
- sample size of 500 eligible participants in six centres was completed in November 2020 and follow-
- 96 up observations were completed on 05-May-2021. A planned interim analysis of data collected in
- 97 200 participants up to 28 days after a single injection of Ad5-nCoV or placebo was completed on

98	21-December-2020 Herein	present the results of final analysis of d	ata collected in 496
70	21 December 2020. Herein,	present the results of multiplis of the	

- 99 participants up to 6 months after a single injection of Ad5-nCoV or placebo.
- 100 Participation was sought through online recruitment advertising and patient databases of the trial 101 sites. All participants underwent detailed screening 1–10 days before vaccination with Ad5-nCoV or 102 placebo (Day 0). Screening included the detection of SARS-CoV-2 RNA using real-time polymerase 103 chain reaction (PCR) via a swab, and SARS-CoV-2 immunoglobulin M (IgM) and immunoglobulin 104 G (IgG) antibody testing to ensure negative results, as well as testing for human immunodeficiency 105 virus (HIV), syphilis, hepatitis B and hepatitis C viruses via blood serum. A detailed medical history 106 for each participant was taken and records included if the participant experienced any COVID-19 107 symptoms and if the participant was in close contact with people suspected or proven to have SARS-108 CoV-2 infection. Participants underwent physical examination (including a neurological 109 examination, vital signs, and body temperature), haematological, biochemical and coagulation 110 testing, urinalysis, electrocardiogram, and when applicable, pregnancy testing as pregnancy (and 111 breastfeeding) was an exclusion criterion. 112 Men and women aged 18–85 years with a body mass index (BMI) between 18.5 and 30.0 kg/m² were

selected to participate if they had no indication of a current or previous SARS-CoV-2 infection (e.g., respiratory infection in last 14 days, axillary temperature \geq 37.0 °C) or close contact with a suspected or confirmed case of SARS-CoV-2 infection. Participants were considered to be eligible if they were in general good health as established by medical history and screening. Those with a range of chronic illnesses, including mental disorders, a history of allergies, recipients of concurrent medication, those with addictions, and those for whom there were concerns over adherence to study protocol were also excluded.

120 Randomisation and Masking

121	The investigational vaccine, Ad5-nCoV, and the placebo were provided by NPO Petrovax Pharm
122	LLC (Moscow, Russia). Both vaccine and placebo were developed by CanSino Biologics Inc.
123	(Tianjin, China) and the Beijing Institute of Biotechnology (Beijing, China). The vaccine was
124	administered with the optimal dose of 5×10^{10} viral particles per 0.5 mL dose, as determined in a
125	previous study [9, 10]; placebo contained vaccine excipients only. The appearance of Ad5-nCoV and
126	placebo syringes and packaging was identical.
127	Eligible participants were randomly allocated to the Ad5-nCoV group or the Placebo group, in a 3:1
128	ratio, by an independent statistician using a validated system including a pseudorandom number
129	generator with a seed value; allocation used block randomisation and stratification by study site.
130	Neither the investigators nor participants were aware of the group assignment. Investigators were
131	trained to use the centralised interactive web response system that was used for randomisation.
132	Randomisation codes were kept by authorised personnel from the responsible contracted
133	organisation.

134 **Procedures**

A single dose (0.5 mL) of Ad5-nCoV or placebo was administered by intramuscular (IM) injection to the upper arm on Day 0. Participants were requested to remain at the site for 2 h after vaccination for study staff to monitor for any systemic or local reactions to vaccination. Following the administration of the vaccine or placebo, participants attended clinic visits on Day 2, Day 7, Day 14, Day 28 and after Month 6. Between Day 28 and Month 6 there were phone calls at Months 2, 3, 4 and 5.

- 140 Determination of serum antibodies against the S protein and RBD of SARS-CoV-2 and the presence
- 141 of neutralising antibodies against SARS-CoV-2 were conducted on Day 0, Day 14, Day 28 and after

142	Month 6; neutralising antibodies against Ad5 were assessed on Day 0, Day 28 and after Month 6.
143	Immunoglobulin G antibodies to the S protein and RBD were determined using indirect enzyme-
144	linked immunosorbent assay kits that involved incubation of serially diluted serum samples with the
145	recombinant antigen (either RBD [SARS-CoV-2-IgG-EIA; XEMA Co. Ltd] or S protein [SARS-
146	CoV-2-IgG-EIA-BEST; Vector-Best]) immobilised to the surface of a 96-well plate. The assays were
147	performed according to the manufacturer's instructions. Horseradish-peroxidase conjugated mouse
148	monoclonal anti-human IgG antibody was used to detect antibodies, visualised with
149	tetramethylbenzidine substrate solution. The detection limit for antibodies against the S protein and
150	RBD of SARS-CoV-2 was 1:100.
151	Anti-coronavirus neutralising antibodies were determined with a microneutralisation assay in which
152	Vero cell (#CCL-81, American Type Culture Collection) monolayers were incubated in 96-well
153	plates with 2-fold serial dilutions (1:10 to 1:1280) of participant serum. Recently thawed and diluted
154	SARS-CoV-2 virus ([GISAID HCoV-19/st_petersburg-3524S/2020] was obtained from the clinical
155	material collection at Smorodintsev Research Institute of Influenza, St. Petersburg, Russia) was
155	added to the wells, and plates were incubated for 1 h at 37 ± 0.5 °C in a humidified incubator. Medium
	-
157	was removed from wells, replaced with a mixture of the most highly diluted (1:1280) serum and
158	virus, and plates were incubated at 37 ± 0.5 °C and 5% CO ₂ for 4 days. Anti-adenovirus neutralising
159	antibodies were also determined using microneutralisation assay; A549 cell monolayers were
160	incubated in 96-well plates with serial dilutions (1:10 to 1:1280) of participant serum and working
161	dilutions of Ad5 (Adenovir; Smorodintsev Research Institute of Influenza). Plates were incubated for
162	2 h at 36±0.5°C and 5% CO ₂ . Medium was removed from wells, replaced with a mixture of diluted
163	serums and working virus dilution, and plates were incubated at 36 ± 0.5 °C and 5% CO ₂ for 72 h. For
164	both microneutralisation assays, results were assessed by visual inspection of cytopathic effects.
165	Serum titres were determined as the maximum dilution at which complete inhibition of viral

reproduction was detected as the result of interaction between virus and specific antibodies; the
detection limit was 1:10. Antibody titres undetectable in serum were assigned values of half of the
detection limits for calculation.
Sequence encoding ΔFurin variant of SARS-CoV-2 S protein (amino acids 1–1213) containing a Cterminal Gly-Gly-6xHis tag was subcloned into the pMCAG-2T vector using the GeneArt Type IIs

171 Assembly Kit, *Bbs*I (Thermo Fisher Scientific), according to the manufacturer's instructions.

172 Recombinant SARS-CoV-2 S protein was expressed in Expi293F cells (Thermo Fisher Scientific) as

173 previously described [16]. Five days following transfection, cells were harvested via centrifugation

174 (15,600 x g), the supernatant was concentrated and diafiltered using the ÄKTATM flux tangential

175 flow filtration system (Cytiva) into buffer A (10 mM phosphate buffer, 2.7 mM KCl, 500 mM NaCl,

176 pH 8.0). The His-tagged S protein was further purified using Ni-NTA agarose resin (Qiagen),

177 washed with buffer A containing 30 mM imidazole and eluted in buffer A with 200 mM imidazole.

178 Using a Slide-A-Lyzer Dialysis Cassette (20K MWCO, Thermo Fisher Scientific), the eluate was

dialysed against PBS (10 mM phosphate buffer, 2.7 mM KCl, 137 mM NaCl, pH 7.5) before use in

180 subsequent experiments.

181 To measure the cellular immune response from T cells (specifically CD8⁺ and CD4⁺ T cells),

182 peripheral blood mononuclear cells (PBMCs) from participants were isolated and tested as described

183 by Shomuradova et al. [16]. In brief, 30 mL of venous blood was collected from the participants and

184 centrifuged via a density gradient (Ficoll; PanEco) for 400 x g for 30 min to isolate PBMCs, which

185 were washed with PBS containing 2 mM EDTA. For the enzyme-linked immunospot (ELISpot)

186 assay, PBMCs (3×10^5 cell/well) were plated into 96-well nitrocellulose plate that was pre-coated

187 with human IFN-γ capture antibody (ImmunoSpot kit Human IFNγ Single-Color ELISpot kit,

188 Cellular Technology Limited) in serum-free test medium (Cellular Technology Limited) containing 1

189 mM GlutaMAX (Gibco) in a final volume of 200 µL/well as previously described [16]. To stimulate

190 the cells, cells were pulsed in duplicates with the S protein at a final concentration of 10 μ g/mL or 191 with a pool of overlapping peptides covering the human S protein (PepTivator SARS-CoV-2 Prot S 192 [Cat. No. 130-126-701; Miltenyi Biotec]) at a final concentration of 1 µM. Plates were incubated at 193 37° C in 5% CO₂ for 18 h, and then the assays were performed according to manufacturer's 194 instructions. Plates were washed twice with PBS, washed twice with PBS + 0.05% Tween-20, and 195 then incubated at room temperature with biotinylated anti-human IFN- γ detection antibody for 2 h. 196 Plates were then washed three times with PBS + 0.05% Tween-20, and then incubated at room 197 temperature with streptavidin-AP for 30 min. After at least two washes, the colorimetric reaction was 198 initiated by adding the substrate components for 15 min at room temperature. The reaction was 199 halted by gently rinsing the plate with distilled water. Spots were counted with the ImmunoSpot 200 Analyzer using the ImmunoSpot software (Cellular Technology Limited). Samples were designated 201 as positive for a T cell response when the mean number of spots in two replicas minus the number of 202 spots in the negative control was ≥ 10 . 203 Evidence of local and general reactogenicity (frequency and nature of systemic and local

204 immunisation reactions on the day of vaccination and within 7 days after vaccination) was sought on 205 Day 0, Day 2 and Day 7. Adverse events (AEs) were monitored from the day of vaccination (Day 0) 206 onwards, during a scheduled phone call that evening, and at all subsequent clinic visits. A physical 207 examination, including neurologic examination, and vital signs, including body temperature, was 208 conducted at all visits (screening, Day 0, Day 2, Day 7, Day 14, Day 28 and Month 6). Participants 209 received telephone calls after 2, 3, 4 and 5 months, and were asked to answer questions to assess 210 safety and determine if they presented with signs of an acute respiratory infection due to COVID-19. 211 Haematology, clinical biochemistry, coagulation testing and urinalysis were conducted at screening, 212 day 2 and Day 28; electrocardiography was performed at screening and on day 2. Immunoglobulin E

(IgE) levels were assessed to determine any allergic effects of vaccine components at screening andon Day 28.

215 **Outcomes**

216 The primary endpoint was the seroconversion rate, specifically the percentage of individuals with a

4-fold or higher increase in antibody titres to the RBD of the SARS-CoV-2 S protein, 28 days after

218 vaccination. Secondary endpoints included the assessment of four outcomes: 1) examining the

219 seroconversion rates in response to RBD, S protein and neutralising SARS-CoV-3 antibodies on Day

14, Day 28 (except for RBD) and at Month 6; 2) geometric mean titres (GMTs) of serum antibodies

against the RBD, S protein and neutralising antibodies against SARS-CoV-2 on Day 14, Day 28 and

222 Month 6 post-vaccination; 3) GMTs of neutralising antibodies against the Ad5 vector on Day 28 and

223 Month 6 post-vaccination; and 4) the cellular immune response as indicated by the secretion of IFN- γ

on Day 14, Day 28 and Month 6 post-vaccination.

225 Exploratory endpoints were the frequency of laboratory-confirmed COVID-19 cases, severe COVID-

19 cases, hospitalisations due to COVID-19 and COVID-19-related deaths (Day 14 to Month 6 post-

vaccination). The safety endpoints were reactogenicity (Day 0 to day 7), the frequency and nature of

AEs (Day 0 to the end of the study [Month 6 Visit]), and the results of physical and laboratory

229 examinations (i.e., haematological tests, urinalysis, serum IgE concentration).

230 Of note, two definitions were used to define seroconversion, one quantitative and one qualitative.

231 The primary and secondary endpoints used the quantitative definition: the proportion of participants

with at least a 4-fold increase in antibody titres against SARS-CoV-2 S protein and/or its RBD,

- 233 specifically. The qualitative analysis was defined as an antibody titre above the lower limit of
- quantification (LLOQ) post-vaccination (if the baseline titre was below the LLOQ), or a 4-fold
- 235 increase over baseline post-vaccination (if the baseline titre was above the LLOQ).

236 Statistical Methods

237	Statistical analysis was performed using SPSS Statistics, Version 26.0 (IBM Corp.). Initially, as part
238	of the interim analysis and to ensure 90% power for the between-group comparison of the primary
239	variable, 180 subjects were to be included. This was based on the assumptions of a 20%
240	seroconversion rate in the Placebo group (based on quantitative analysis), superiority of the vaccine
241	group of \geq 30% (conservative assumption, odds ratio = 4), corrected two-sided significance level of
242	0.02616 (one-sided level of 0.01308) and the randomisation ratio of 3:1. Considering potential
243	dropouts from the study during the initial observation period of 28 days (10% of subjects), the total
244	number of randomised participants was increased to 200. To provide more detailed safety and
245	efficacy data (including age subgroups) and to descriptively present the frequency of confirmed
246	COVID-19 cases that occurred within 6 months post-vaccination (except for COVID-19 cases that
247	developed during the first 14 days after the vaccination), a sample size of 500 was selected.
248	An unblinded interim analysis was originally planned and conducted in this clinical trial when
249	obtaining partial information to evaluate the primary endpoint, gathered from the first 200
250	randomised volunteers and based on the results collected up to Day 28 (Visit 5), including the data
251	for those who left the trial before Visit 5. Subsequently, an alpha spending function (that is, an
252	increasing function of the proportion of the maximum sample size) of the Pocock type was employed
253	to adjust the level of significance due to the multiple comparisons of the primary variable in the
254	planned interim and final analysis sets. Analyses were performed with bilateral alpha levels of
255	0.02616 and 0.03039 on the interim and final analysis sets, respectively (with a total bilateral
256	significance level of 5%).

Variables representing the seroconversion rate (the proportion of participants with at least a 4-fold
increase in antibody titres) were tabulated by evaluation time-points and treatment groups, and two-

sided Clopper-Pearson 95% confidence intervals (CIs) presented. Comparative analysis of the

- 260 primary endpoint (seroconversion, quantitative definition) was performed using the Cochran-Mantel-
- 261 Haenszel test and the chi-squared test (or Fisher's exact test).
- 262 Antibody GMTs and neutralising antibody GMTs were presented and compared by evaluation time
- 263 points based on the calculated 95% CIs using two-way analysis of variance (ANOVA) following
- 264 logarithmic transformation. Mean log-transformed differences between the study groups (vaccine
- and placebo) were evaluated with the corresponding 95% CI. The point estimates of the mean
- 266 differences and the corresponding CIs were back-transformed.
- 267 Geometric mean fold-increases in antibody and neutralising antibody titres for each treatment group

and each antibody GMT evaluation time point were assessed with the corresponding two-sided 95%

269 CIs following log-transformation, point estimation of the difference and CIs, and back-

270 transformation of obtained values. Between-group comparisons were performed using ANOVA

- 271 following the logarithmic transformation. Results from the ELISpot assay to assess differences in
- 272 cellular immunity were analysed using Mann-Whitney test with Bonferroni adjustment of p-values.

273 Statistical significance was accepted at p<0.05. Results for immunogenicity analyses are presented 274 for the full analysis set ([FAS], which included all eligible participants who received a dose of 275 vaccine and provided at least one immunogenicity assessment result). Results for the per protocol set 276 ([PPS], which included members of the FAS who received a dose of vaccine according to the 277 randomisation and study scheme and provided data for immunogenicity assessment before and after 278 vaccination in line with the study scheme, did not receive a prohibited therapy, had no significant 279 protocol deviations that could have impacted efficacy assessment and did not develop COVID-19 280 within the first 14 days post-vaccination) were similar to those of the FAS and are therefore not 281 presented. Cellular immunity results were analysed in participants from the FAS that provided at

- 282 least one cellular immunity assessment result. Prophylactic efficacy results are presented for the PPS
- 283 (for efficacy analysis). The safety analysis set included all randomized volunteers who received a
- dose of the vaccine.

285 **Patient and Public Involvement**

- 286 Participants were not directly involved in the development, implementation, or interpretation of this
- study due to the requirement for a quick response to the rapidly-evolving coronavirus pandemic.

288 Data Sharing

- 289 The Authors commit to making the relevant anonymised participant level data available upon
- 290 reasonable request for 3 years following publication of this study. Requests should be directed to the
- 291 corresponding author.

292 **RESULTS**

- 293 Out of the 783 participants who were screened, this analysis included 500 eligible participants
- intended for vaccination at six locations in the Russian Federation between 11 September 2020 and
- 11 November 2020. Of these, 374 participants were randomised to the Ad5-nCoV group and 126 to
- the Placebo group (Fig. 1). The safety analysis set included 496 participants, the FAS for
- immunogenicity analysis included 495 participants, and the PPS for efficacy analysis included 481
- 298 participants.
- 299 Fig. 1. Participant flow diagram. AE, adverse event; FAS, Full Analysis Set; PPS, Per-Protocol Set.
- 300 The mean age of participants was 41.2 years (range 18–79 years), with 300 (60.5%) participants aged
- 301 18–44 years, 161 (32.5%) aged 45–59 years, and 35 (7.1%) aged 60 years or older (Table 1). There
- 302 were more males (297 out of 496 [59.9%]) than females. The vast majority of the participants
- 303 (99.4%) were white race and 3 participants were Asian. Baseline characteristics were largely similar
- 304 across groups.

305 **Table 1. Participant Demographics.**

	Ad5-nCoV N=372	Placebo N=124	Total N=496
Age (years[%])		·	•
18–44 years	223 (59.9)	77 (62.1)	300 (60.5)
45–59 years	122 (32.8)	39 (31.5)	161(32.5)
≥ 60 years	27 (7.3)	8 (6.5)	35 (7.1)
Mean	41.2	41.0	41.2
Sex (n[%])			
Male	151 (40.6)	48 (38.7)	199 (40.1)
Female	221 (59.4)	76 (61.3)	297 (59.9)
Race (n[%])			
White	371 (99.7)	122 (98.4)	493 (99.4)
Asian	1 (0.3)	2 (1.6)	3 (0.6)
Country (n[%])			
Russia	372 (100%)	124 (100%)	496 (100%)
Body Mass Index (kg/m ²)			
Mean	25.03	24.7	24.94
Minimum	18.6	18.6	18.5
Maximum	30.0	29.9	30.0
Underlying Disease (n[%])			
Yes	34 (22.8)	9 (18.0)	43 (21.6)
No	115 (77.2)	41 (82.0)	156 (78.4)
Prior Disease (n[%])			
Yes	176 (47.3)	56 (45.2)	232 (46.8)
No	93 (62.4)	36 (72.0)	129 (64.8)

306 Immunogenicity and efficacy results

307 Baseline antibody titres of the participants in the FAS (Ad5-nCoV; placebo) were similar for anti-

308 RBD antibodies (50.1; 50.0), anti-S protein (50.3; 50.3), neutralising anti-SARS-CoV-2 antibodies

309 (5.0; 5.0), as well as neutralising antibodies against the Ad5 vector (11.3; 8.8). Administration of the

310	Ad5-nCoV vaccine led to a marked increase in anti-RBD antibody response compared with placebo
311	across the FAS, with GMTs of 138.61 (95% CI: 125.60; 152.97) on Day 14 and 405.32 (95% CI:
312	361.58; 454.46) on Day 28; differences compared with placebo achieved statistical significance on
313	days 14 and 28 (both p<0.001; Fig. 2). Six months following vaccination, antibodies levels in the
314	vaccinated group remained high with a mean GMT of 153.07 (95% CI: 133.08; 176.08).
315	Interestingly, a notable increase in anti-RBD antibodies at Month 6 was also observed in the Placebo
316	group, which could be attributed to an asymptomatic infection (GMT of 115.50 [95% CI: 88.84;
317	150.18], p=0.064).
210	

Fig. 2. Geometric mean titre (GMT) of serum antibodies against the RBD and SARS-CoV-2 S

protein on Day 0, Day 14, Day 28 and Month 6 after vaccination. The GMTs with 95% CI are shown

320 for serum antibodies against Ad5 (ADENOVAB), SARS-CoV-2 neutralising antibodies

321 (SAR2NAB), RBD (SAR2RBD) and S protein (SAR2S) (***, p<0.001). Ad5, adenovirus type-5; CI,

322 confidence interval; RBD, receptor binding domain; S, spike; SARS-CoV-2, severe acute respiratory

323 syndrome coronavirus 2.

324 In the primary analysis on Day 28, 285 (78.5%, 95% CI: 73.9; 82.6) of 363 participants in the Ad5-

325 nCoV group showed seroconversion of RBD-specific antibodies compared with 7 (5.9%; 95% CI:

326 2.4, 11.7) of 119 participants in the Placebo group, which was indicative of a significant treatment

327 difference (Ad5-nCoV – placebo was 72.6% [95% CI: 65.7, 78.1; p<0.001]). On Day 14, 152/359

328 (42.3%) participants from the Ad5-nCoV group showed seroconversion of RBD-specific antibodies

329 compared with the Placebo group ($p\Box 0.001$). However, at Month 6, 140/353 (39.7%) participants in

330 the Ad5-nCoV group showed a slight reduction in the seroconversion rate of RBD-specific

antibodies compared with the Placebo group (35/101 [34.7%]; p=0.354).

332 The vaccine dose also induced a significant increase in anti-S protein antibody responses, with a 333 GMT of 288.60 on Day 14 (95% CI: 258.05; 322.78) compared with the Placebo group (51.49 [95% 334 CI: 42.34; 62.62; p \[0.001]); moreover, the significant increase in anti-S protein was also observed 335 on Day 28, with a GMT of 676.87 (95% CI: 607.44; 754.40) compared with the Placebo group 336 (61.31 [95% CI: 50.71; 74.11; p 0.001]). This increasing trend in anti-S protein antibody responses 337 continued even at Month 6, with a GMT of 293.22 (95% CI: 252.12; 341.11) compared with the 338 Placebo group (145.85 [95% CI: 109.85; 193.64; p 0.001]) (Fig. 2). Similarly, 239 (66.6%, 95% CI: 339 61.4; 71.4) of 359 participants had seroconverted with S protein-specific antibodies by Day 14 340 compared with 1 (0/8%, 95% CI: 0.0; 4.6) of 118 the Placebo group ($p \square 0.001$). Additionally, 329 341 (90.6%, 95% CI: 87.2; 93.4) of 363 participants also had significantly elevated levels of 342 seroconversion with S protein-specific antibodies by Day 28 compared with the Placebo group 343 (6.7% [95% CI: 2.9; 12.8; p□0.001]). Treatment difference on Day 28 was 65.9% (95% CI; 59.6; 344 71.3) compared with the Placebo group (p<0.001). At Month 6, 222 (62.9% (95% CI: 57.6; 67.9) of 345 353 participants had seroconverted with S protein-specific antibodies compared to the Placebo group 346 (41 [40.6%] of 101 participants; $p \square 0.001$). 347 Administration of the Ad5-nCoV vaccine induced significant greater neutralising antibody responses 348 to SARS-CoV-2 than placebo (p<0.001), with GMTs of 8.78 on Day 14 (95% CI: 8.19; 9.41) and 349 16.73 on Day 28 (95% CI: 15.36; 18.22). At Month 6, significantly greater neutralising antibody 350 responses to SARS-CoV-2 were still present, with a GMT of 19.50 (95% CI: 16.97; 22.41) compared 351 with a GMT of 8.94 (95% CI: 6.63; 12.04) in the Placebo group ($p \square 0.001$) (Fig. 3). Seroconversion 352 for neutralising antibodies to SARS-CoV-2 occurred in 75 (24.4%, 95% CI: 19.7; 29.5) of 308 353 participants on Day 14. No increase in neutralising antibody from baseline was observed in the 354 Placebo group. On Day 28, seroconversion for neutralising antibodies to SARS-CoV-2 occurred in 355 183 (59.0%, 95% CI: 53.3; 64.6) of 320 participants; notably, greater proportions were observed in

356	the Ad5-nCoV group on days 14 and 28 compared with the Placebo group (p<0.001). At Month 6,
357	149 (48.9%, 95% CI 43.1; 54.6) of 305 participants had a 4-fold or greater increase of neutralising
358	antibodies compared with the Placebo group (32/93 [34.4%, 95% CI: 24.9; 45.0; p=0.012]).
359	Fig. 3. Seroconversion rates of the neutralising antibodies against SARS-CoV-2 and the
360	seroconversion rate against the RBD and SARS-CoV-2 S protein on Day 0, Day 14, Day 28 and
361	Month 6 after vaccination. The seroconversion rates with 95% CI are shown for serum antibodies
362	against Ad5 (ADENOVAB), SARS-CoV-2 neutralising antibodies (SAR2NAB), RBD (SAR2RBD)
363	and S protein (SAR2S) (***, p<0.001; *, p<0.05). Ad5, adenovirus type-5; CI, confidence interval;
364	RBD, receptor binding domain; S, spike; SARS-CoV-2, severe acute respiratory syndrome
365	coronavirus 2.
366	Almost all participants had neutralising antibodies against the Ad5 vector at baseline: 317/372
367	(85.2%) participants who received Ad5-nCoV and 106/124 (85.5%) who received placebo. For most
368	participants, the antibody titre to Ad5 was low (≤1:200) (Fig. 4); very few participants had high
369	(>1:200) levels of pre-existing antibodies to Ad5 (7/424, 1.7%). Geometric mean anti-Ad5 antibody
370	titre in participants with low pre-existing anti-Ad5 antibodies increased from 11.3 at baseline
371	(n=317) to 36.5 at Day 28 (n=353), which then increased further to 48.3 (n=355) at Month 6.
372	Corresponding values for the very few participants with pre-existing immunity to Ad5 >1:200
373	showed an increase from 320.0 at baseline (n=6) to 359.2 at Day 28 (n=6) and a further increase to
374	557.2 at Month 6 (n=6). The GMT of neutralising antibodies against the Ad5 vector in all
375	participants who received Ad5-nCoV was 11.28 on Day 0 (95% CI: 9.95; 12.78), 36.48 on Day 28
376	(95% CI: 30.72; 43.30) and 48.34 at Month 6 (95% CI: 40.25; 58.05), with significant levels of
377	neutralising antibodies against Ad5 present at Day 28 and Month 6, compared with the Placebo
378	group (p□0.001).

Fig. 4. Titre distribution of anti-Ad5 antibodies on Day 0, Day 28 and Month 6 after vaccination in
those from either the Ad5-nCoV or Placebo groups.

- 381 The effect of pre-existing immunity to Ad5 on the immunological responses to the vaccine was
- 382 studied. As presented in Fig. 5, the increase of GMTs to anti-RBD antibodies after vaccination in the
- Ad5-nCoV group was comparable between patients with high (>1:200) and low (≤1:200) baseline
- titres of antibodies to Ad5 up to Day 28, although this observation may be attributed to the small
- number of patients with pre-existing high Ad5 titres (n=7).
- **Fig. 5**. Antibody responses to SARS-CoV-2 vaccine in those with pre-existing immunity to Ad5.
- 387 Geometric mean titre (GMT) of titres in response to anti-Ad5 antibody (ADENOVAB), anti-RBD
- 388 (SAR2RBD) and S protein (SAR2S) antibodies as well as neutralising SARS-CoV-2 antibodies
- 389 (SAR2NAB) on Day 0, Day 14, Day 28 and Month 6 after vaccination. Volunteers are divided into
- seven (from 1:5 to 1:320) cohorts based on their pre-existing anti-Ad5 antibody levels. Ad5,
- adenovirus type-5; CI, confidence interval; RBD, receptor binding domain; S, spike; SARS-CoV 2,
- 392 severe acute respiratory syndrome coronavirus 2.
- 393 Pearson's correlation coefficients between baseline GMTs to Ad5, GMTs to RBD and S protein
- 394 antibodies as well as neutralising SARS-CoV-2 antibodies were calculated. There was a negative
- 395 correlation of -0.36 between baseline GMT to Ad5 and GMT to RBD on Day 14 that weakened
- 396 to -0.05 at 6 months post-vaccination. The correlations between baseline GMT and GMTs to S
- 397 protein and neutralising SARS-CoV-2 antibodies decreased by Month 6 (Fig. 6). The decrease in
- 398 correlation was less pronounced between GMTs to RBD, indicating that the relationship between
- 399 levels of baseline Ad5 GMTs to the COVID-19 humoral immune response weakens over time
- 400 following vaccination.

401	Fig. 6. Pearson's correlation coefficient between GMTs versus anti-Ad5 antibodies (ADENOVAB)
402	in response to anti-RBD (SAR2RBD) and S protein (SAR2S) antibodies as well as neutralising
403	SARS-CoV-2 antibodies (SAR2NAB) on Day 0, Day 14, Day 28 and Month 6 after vaccination. The
404	correlation coefficients with 95% CI are shown. Ad5, adenovirus type-5; CI, confidence interval;
405	RBD, receptor binding domain; S, spike; SARS-CoV 2, severe acute respiratory syndrome
406	coronavirus 2.
407	The effect of the vaccination on cellular immune responses was studied in a subgroup of 69
408	participants recruited by Moscow research centres (Ad5-nCoV group, n=50 volunteers; placebo
409	group, n=19). The presence of SARS-CoV-2 specific $CD8^+$ and $CD4^+$ T cells in venous blood
410	samples was assessed by counting the number of spot-forming cells (SFCs; i.e., IFN- γ secreting
411	cells) in an ELISpot assay in which isolated PBMCs were stimulated with either full-length S protein
412	or a pool of overlapping peptides covering the S protein (i.e., peptide pool). The most pronounced
413	response occurred on Day 14 after the Ad5-nCoV vaccination in which the median number of SFCs
414	was 32.8 (Quartile [Q]1: 19.0, Q3: 78.9) when stimulated with the peptide pool and 32.2 (Q1: 16.0,
415	Q3: 99.9) when stimulated with full-length S protein (Fig. 7A and 7B, respectively). For cells
416	stimulated with the peptide pool, the median number of SFCs decreased to 5.5 (Q1: 1.5, Q3: 12.2) on
417	Day 28 and further still to 1.5 (Q1: 0, Q3: 8.5) at Month 6. When stimulated with full-length S
418	protein, the number of SFCs increased to 4.5 (Q1: 3.0, Q3: 12.5) on Day 28 and 5.5 (Q1: 0.75, Q3:
419	13.8) by 6 months post-vaccination.

Fig. 7. Assessing the cellular immune response to SARS-CoV 2 vaccine using an enzyme-linked
immunospot (ELISpot) assay. Peripheral blood mononuclear cells (PBMCs) were isolated from
blood samples taken from participants from either the Placebo or Ad5-nCoV group. PBMCs isolated
on Day 0, Day 14, Day 28 and Month 6 after vaccination were stimulated with (A) a pool of peptides
that span the S protein (i.e., peptide pool) or (B) the full-length S protein. The response of T cells

425 was determined by counting IFN- γ -positive spot-forming cells (SFCs). Spots were quantified via an 426 automated digital image. The median with quartiles is the plotted, the dotted line indicates the 427 positivity threshold (***, p<0.001; **, p<0.01). Ad5, adenovirus type-5; S, spike; SARS-CoV-2,

428 severe acute respiratory syndrome coronavirus 2.

429 Compared with the response observed in the Placebo group, those in the Ad5-nCoV group displayed

430 significantly higher numbers of IFN-γ-positive T cells, regardless of how the cells were stimulated,

431 on Days 14 (p<0.001) and 28 (p<0.01). However, 6 months post-vaccination, the differences

432 between the groups were not statistically significant when cells were stimulated with the full-length

433 S protein (p=0.6) or with the peptide pool (p=1.0).

434 The percentage of participants who had an IFN- γ response above the threshold following stimulation 435 with the peptide pool on Day 14 in the Ad5-nCoV group was 91.7% (95% CI: 80.4; 96.7), whereas 436 no participants were positive in the Placebo group. During the follow-up period, the response rate 437 decreased for those in the Ad5-nCoV group and the percentage of patients that displayed an IFN-y 438 response on Day 28 was 37.2% (95% CI: 24.4; 52.1), whereas no participants were positive in the 439 Placebo group. At Month 6, the percentage of patients displayed an IFN-y response was 21.2% and 440 12.5% in the Ad5-nCoV and Placebo groups, respectively. The trend of an IFN- γ response for cells 441 stimulated with full-length S protein was similar to the trend observed when cells were stimulated 442 with the peptide pool. The percentage of participants who displayed an IFN- γ response following 443 stimulation with full-length S protein in the Ad5-nCoV group on Day 14 was 83.3% (95% CI: 70.4; 444 91.3), whereas no participants were positive in the Placebo group. During the follow-up period, the 445 response rate markedly decreased for those in the Ad5-nCoV group and the percentage of patients 446 that displayed an IFN-γ response on Day 28 was 30.2 % (95% CI: 18.6; 45.1), whereas there was one 447 participant who had an IFN-y response in the Placebo group. At Month 6, 31% of patients (95% CI:

- 448 20.4; 46.2) displayed an IFN-γ response that was comparable to 25% of patients in the Placebo group
- 449 following stimulation with the full-length S protein.
- 450 Of note, 31 of the participants were confirmed to have COVID-19 within 14 days post-vaccination.
- 451 Thirteen participants were from the Placebo group (13/31 [11.32%]), whereas 18/31 (4.97%)
- 452 participants were from the Ad5-nCov group (p=0.023). Cases of severe COVID-19 (with the
- 453 exception of COVID-19 cases that occurred during the first 14 days post-vaccination) were
- registered in only 2 (1.7%) participants, both of whom were from the Placebo group. Both of these
- 455 severe COVID-19 cases required hospitalization. No deaths from COVID-19 were registered.

456 Safety evaluation

- 457 Systemic (general) immunisation reactions
- 458 A total of 113 (22.8%) of the 372 participants who received the Ad5-nCoV vaccine reported
- 459 systemic reactions (Table 2). The incidence of systemic reactions was significantly higher than in the
- 460 Placebo group, where 13 (10.5%) of the 124 participants reported systemic reactions.

	Ad5-nCoV N = 372	Placebo N = 124	Total N = 496
Systemic (general) immunisation reactions	100 (26.9%)/162	13 (10.5%)/20	113 (22.8%)/182
Grade 1	78 (21.0%)/131	10 (8.1%)/16	88 (17.7%)/147
Grade 2	17 (4.6%)/26	3 (2.4%)/4	20 (4.0%)/30
Grade 3	5 (1.3%)	0	5 (1.0%)
Local immunisation reactions	106 (28.5%)/180	2 (1.6%)/4	108 (21.8%)/184
Grade 1	91 (24.5%)/154	2 (1.6%)/4	93 (18.8%)/158
Grade 2	15 (4.0%)/26	0	15 (3.0%)/26
Grade 3	0	0	0
AEs (except for immunisation reactions)	152 (40.9%)/365	38 (30.6%)/75	190 (38.3%)/440
AEs related to vaccination	130 (34.9%)/280	25 (20.2%)/43	155 (31.3%)/323
Grade 1	106 (28.5%)/246	20 (16.1%)/36	126 (25.4%)/282
Grade 2	21 (5.6%)/30	5 (4.0%)/7	26 (5.2%)/37
Grade 3	3 (0.8%)/4	0	3 (0.6%)/4
AEs related to vaccination and registered during the first 7 days after vaccination	123 (33.1%)/244	25 (20.2%)/42	148 (29.8%)/286
Serious AEs	1 (0.3%)/1	5 (4.0%)/5	6(1.2%)/6
Death	0	0	0
Early discontinuation due to AE	0	0	0

461 Table 2. Summary of adverse events (AEs) by safety analysis set.

462 Data presented as the number of participants with adverse events per category (%)/number of AE records.

463

464 The most commonly reported reactions in the Ad5-nCoV group included increase in body

465 temperature (20.2%), headache (5.9%), fatigue (5.4%), myalgia (4.8%) and arthralgia (1.9%; S1

466 Table). For most participants, general immunisation reactions were mild (Grade 1, 21.0%). Moderate

467 (Grade 2) reactions occurred in 4.6% of participants and included increase in body temperature,

468 headache, myalgia, arthralgia, and fatigue. Severe (Grade 3) reactions, including an increase in body

temperature (39.0–40.0 °C), occurred in 4 participants, and myalgia occurred in only 1 participant

470 (Table 2 and S2 Table).

471 In the Placebo group, reactions included increase in body temperature (6.5%), headache (4.8%),

- 472 fatigue (5.4%) and diarrhoea (0.8%). These AEs were mild or moderate; no severe reactions were
- 473 reported (Table 2, S1 Table and S2 Table).
- 474 There were no fatal outcomes. During the first 7 days after vaccination, a total of six serious AEs
- 475 (SAEs) were reported (Table 2): one SAE in 1 (0.3%) participant from the Ad5-nCoV group and five
- 476 SAEs in 5 (4.0%) participants from the Placebo group. Of note, two of the participants from the
- 477 Placebo group were hospitalised due to COVID-19. For the only SAE event experienced by a
- 478 participant from the Ad5-nCoV group, the event was found to have no connection with the study
- 479 drug. The SAEs are described in S3 Table.

480 Injection site reactions

- 481 Injection site reactions occurred in 106 participants (28.5%) who received the Ad5-nCoV vaccine.
- 482 By comparison, only 2 participants in the Placebo group (1.6%) experienced an injection site
- 483 reaction including swelling and pain or induration (S4 Table), all of which were Grade 1 in severity
- 484 (S5 Table). The most common reactions included pain (16.9%), erythema (14.8%) and induration at
- 485 the injection site (4.8%) (S4 Table). As listed in S5 Table, for most participants, local injection site
- 486 reactions were mild (24.5%). Fifteen participants (4.0%) who received the Ad5-nCoV vaccine had a
- 487 moderate reaction that included pain, erythema, swelling or induration at the injection site. No severe
- 488 reactions were reported.

489 *Other adverse events (excluding immunisation reactions)*

- 490 A total of 190 participants (38.3%) reported other AEs during the 6 months after vaccination;
- 491 152/365 (40.9%) participants from the Ad5-nCoV group and 38/75 (3.6%) participants from the
- 492 Placebo group. As listed in Table 2, these AEs were assessed by the investigators as related to the

493	vaccine (Ad5-nCoV: 34.9%; Placebo: 20.2%). The majority of vaccine-related AEs were reported
494	during the first 7 days after vaccination (Ad5-nCoV: 33.1%; Placebo: 20.2%). In both groups, the
495	most common AEs were out-of-range laboratory measurements: 34.4% reported by participants in
496	the Ad5-nCoV group and 16.9% from the Placebo group. The most pronounced differences in AE
497	incidence in the Ad5-nCoV group compared with the Placebo group were: increases in C-reactive
498	protein (17.6% vs. 2.4%), monocytes (4.0% vs. 0%) and aspartate aminotransferase (1.6% vs. 1.6%)
499	as well as a decrease in neutrophils (6.2% vs 2.4%) (S6 Table).
500	For most participants, AEs were mild, reported in 28.5% of the Ad5-nCoV group and 16.1% of the
501	Placebo group. Moderate events were registered in 5.6% of participants who received the Ad5-nCoV

502 vaccine and 4.0% who received the placebo. By comparison, SAEs occurred in 0.8% of participants

503 in the Ad5-nCoV group, but none in the Placebo group; these included increases in C-reactive

504 protein (0.5%) and blood fibrinogen levels (0.5%).

For most participants, general and injection site reactions and AEs resolved within 7 days aftervaccination.

507 Results of the analysis of laboratory parameters demonstrated a trend towards an increase in C-

508 reactive protein levels, an increase in the red cell sedimentation rate, an increase in the mean

509 percentage of monocytes, and a decrease in the mean percentage of neutrophils after administration

510 of Ad5-nCoV. The changes in the examined laboratory parameters were pronounced the day after

511 vaccination, but had largely resolved by Day 28.

512 The proportion of participants in the Ad5-nCoV group with elevated IgE at Day 28 showed no

513 changes from screening: 73/372 (19.6%) to 76/365 (20.8%).

514 **DISCUSSION**

515 In this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial including 500 adult 516 participants aged 18-85 years (mean age: 41.2 years), the immunogenicity, efficacy and safety of the 517 Ad5-nCoV COVID-19 vaccine was assessed up to 6 months after vaccination. Both study groups 518 (Ad5-nCoV and placebo) had similar baseline characteristics. A single immunisation with the Ad5-519 nCoV vaccine led to a marked immune response. The primary endpoint (seroconversion rate of anti-520 RBD antibodies on Day 28 after vaccination) and all secondary endpoints on Day 28 after 521 vaccination showed statistically significant superiority of the Ad5-nCoV vaccine compared with 522 placebo (p<0.001). 523 The seroconversion rate of antibodies against the RBD of the SARS-CoV-2 S protein (78.5%) and of 524 neutralising antibodies against SARS-CoV-2 (59%) on Day 28 were similar to the results obtained 525 during the interim analysis of a phase 2 clinical study conducted in China. The seroconversion rate of 526 anti-RBD antibodies in the Ad5-nCoV group was 97% (95% CI: 92; 99), and the seroconversion rate 527 of neutralising antibodies against live SARS-CoV-2 was 47% (95% CI: 39; 56) [9]. 528 The GMTs of anti-RBD, S protein-specific antibodies and neutralizing SARS-CoV-2 antibodies 529 increased significantly at Month 6 post-vaccination in the Placebo group, not by Day 14 or Day 28. 530 We theorized two possible explanations. First, some individuals might have been asymptomatic 531 while infected with COVID-19, or COVID-19-positive patients did not report their symptoms to the 532 study's physicians. Second, individuals in the Placebo group might have taken a commercially 533 available antibody test that was widely available in Russia and decided to receive another 534 vaccination after observing their low antibody titres, thereby confounding their treatment status. Two 535 participants were excluded from the PPS for this reason, but many more could have been unreported.

536 Adenovirus exposure is common. Pre-existing anti-Ad5 immunity may affect the immunogenicity of 537 Ad5-based vaccines, and as a result, their efficacy against COVID-19. However, the proportion of 538 individuals with high anti-Ad5 titres in a population varies across regions [17–19] and it is unclear to 539 what extent previous exposure influences existing titres and the speed of their decline. A titre of 540 1:200 was selected as the cut-off point for low and high anti-Ad5 antibodies during the phase 1 and 2 541 studies in China. Those with low baseline anti-Ad5 titres (≤1:200) had RBD-specific antibody and 542 neutralising antibody levels roughly twice as high as those with high baseline anti-Ad5 titres 543 (>1:200) [9, 10]. Our data analysis used a cut-off of 1:200 in line with the Chinese studies, but given 544 the variable levels of anti-Ad5 titres around the world, a limit of 1:200 may not necessarily be 545 appropriate in all regions. The selection of an appropriate cut-off point in the current study was 546 hampered by a lack of published data on anti-Ad5 levels in the Russian population. Among the 547 Russian participants, those with baseline levels of anti-Ad5 antibodies showed a very small group of 548 7 (1.4%) participants with titres of approximately 1:320 (Fig. 4). All of them were in the subgroup of 549 participants aged 18 to 45 years.

550 In this study, we uncovered the response of pre-existing immunity to Ad5 and showed how it affects 551 subsequent humoral immune responses as well as the longevity of immunity to COVID-19. In 552 participants vaccinated with Ad5-nCoV, there was no difference in humoral immunity to COVID-19 553 between those with baseline Ad5 titres above or below the cut-off of 1:200. However using a cut-off 554 of 1:5, we showed that those with baseline Ad5 titres of 1:5 displayed a greater amount of GMTs to 555 anti-RBD and S protein antibodies as well as neutralising SARS-CoV-2 antibodies than those with a 556 higher baseline ratio of Ad5 titres (Fig. 5). The relationship between the levels of baseline Ad5 557 GMTs to the respective antigen tends to weaken over time following vaccination (Fig. 6). Studies 558 with longer follow-up periods would help to clarify the longevity of the immune response in those

vaccinated with Ad5-nCoV. Moreover, studies with a larger dataset would help to determine if preexisting immunity to Ad5 correlates to protection efficacy.

561 Our study provides data on the incidence of anti-Ad5 immunity in the Russian population, admittedly

562 in a relatively small sample size. Almost all participants had pre-existing neutralising antibodies to

563 Ad5, although levels were generally very low. No such data were available before this study, and

only limited and highly variable data are available for the level of Ad5 immunity in Europe.

565 The results from this study demonstrate that the experimental Ad5-nCoV vaccine has a good safety

566 profile comparable with the findings of preceding clinical trials in healthy adults. Most post-

567 vaccination AEs were mild or moderate in severity. Although the proportions of participants who

568 reported adverse reactions such as an increase in body temperature, headache, and pain at the

569 injection site were higher in those that received the Ad5-nCoV vaccine, adverse reactions within

570 28 days were generally mild to moderate and the majority resolved within 7 days after vaccination.

571 All Grade 3 AEs occurred among participants from the Ad5-nCoV group and were similar to

572 commonly reported AEs after other types of immunisation.

573 There are currently multiple recombinant Ad-vectored COVID-19 candidate vaccines in

development [4–7, 9, 10, 20, 21]. The most relevant comparator vaccine in terms of the practicalities

of storage, transport and administration is the Ad26.COV2.S vaccine [22]. Like the Ad5-nCoV

576 vaccine, it can be administered as a single dose, stored in a standard refrigerator without the need for

577 ultra-low temperature freezing and is stable at room temperature prior to administration. An interim

analysis of Ad26.COV2.S showed that vaccine-induced neutralising antibodies against wild-type

- 579 virus were detected in 95% or more of participants on day 29 after dosing. Our qualitative analysis
- used a similar definition of seroconversion to that used to assess the Ad26.COV2.S vaccine [22]; as
- 581 well as including participants who seroconverted from below the LLOQ of the assay at baseline to

582	detectable antibodies at Day 28, it included those with a 4-fold or greater increase in antibody titre
583	over the same period. The Ad5-nCoV vaccine provided a similar antibody response to
584	Ad26.COV2.S: 95.9% of subjects developed antibodies to the S protein and 92.5% to the smaller
585	anti-RBD region by Day 28.
586	This study has several limitations. First, the participants included in this study were all white,
587	although conversely, this also provided the first data in a non-Chinese, European population. Second,
588	this trial did not include children or pregnant women, and there were only a small number of older
589	adults (35 were ≥60 years in the Ad5-nCoV group). An ideal candidate vaccine for COVID-19
590	should cover vulnerable populations of all ages. Anti-S protein-specific antibodies have been
591	reported to decline rapidly in individuals who have recovered from COVID-19, especially those who
592	were asymptomatic or had mild symptoms [23]. Third, the sample size was relatively small and some
593	of the calculated 95% CIs were wide. Finally, virus mutation, an emerging problem, may reduce the
594	effectiveness of current vaccines [24]. It is not known whether participants of this study were
595	exposed to any COVID-19 variants. Further study is underway to determine neutralising antibodies
596	to the widely circulating variants following vaccination with Ad5-nCoV, which include but are not
597	limited to the Alpha (B.1.1.7), Beta (B.1.351) and Gamma (P.1) variants.

598 Conclusions

599 Analysis of data from this phase 3 trial demonstrated the immunogenicity and safety of this Ad5-

600 vector based COVID-19 vaccine. More data are required to determine whether this vaccine reduces

601 infections and transmission. Overall, this stable, single-dose vaccine could contribute to the global

602 fight against the evolving SARS-CoV-2 virus.

603 **DECLARATIONS**

604 Acknowledgements

- 605 Medical writing support was provided by Dr Justin Cook, Dr Antria Siakalli and Dr Caitlin Tolbert
- of Niche Science and Technology Ltd, Richmond-upon-Thames, Surrey, UK; this was paid for by
- 607 NPO Petrovax Pharm LLC, 1, Moscow region, Russian Federation.

608 Supporting Information

- 609 S1 Protocol. Study Protocol.
- 610 S1 Checklist. CONSORT Checklist.
- 611 S1 Table. Systemic (general) post-vaccination reactions (Safety population).
- 612 S2 Table. Systemic (general) post-vaccination reactions by severity (Safety population).
- 613 S3 Table. Summary of all severe adverse events that led to hospitalisation or prolonged
- 614 hospitalisation.
- 615 S4 Table. Local post-vaccination reactions (Safety population).
- 616 S5 Table. Local post-vaccination reactions by severity (Safety population).
- 617 S6 Table. Other adverse events unrelated to vaccination reactions (Safety population).

618 Author Contributions

- 619 **Conceptualization:** Vitalina Dzutseva, Grigory A. Efimov, Mikhail Tsyferov, Anton Tikhonov,
- 620 Andrei Afanasiev.

- 621 **Data Curation:** Dmitry Lioznov, Irina Amosova.
- 622 Formal Analysis: Dmitry Zubkov.
- 623 Investigation: Savely A. Sheetikov, Ksenia V. Zornikova, Yana Serdyuk, Grigory A. Efimov,
- 624 Dmitry Lioznov, Irina Amosova.
- 625 Methodology: Grigory A. Efimov, Dmitry Lioznov, Tao Zhu, Luis Barreto, Vitalina Dzutseva.
- 626 **Project Administration:** Vitalina Dzutseva, Mikhail Khmelevskii.
- 627 Resources: Savely A. Sheetikov, Ksenia V. Zornikova, Yana Serdyuk, Grigory A. Efimov, Vitalina
- 628 Dzutseva.
- 629 **Supervision:** Grigory A. Efimov, Vitalina Dzutseva, Dmitry Lioznov.
- 630 Validation: Irina Amosova, Grigory A. Efimov, Dmitry Lioznov.
- 631 **Visualisation:** Dmitry Zubkov, Anton Tikhonov.
- 632 Writing Original Draft Preparation: Anton Tikhonov, Nadezhda Khomyakova, Andrei

633 Afanasiev.

- 634 Writing Review and Editing: Anton Tikhonov, Nadezhda Khomyakova, Dmitry Lioznov,
- 635 Grigory A. Efimov, Mikhail Tsyferov, Irina Amosova, Savely A. Sheetikov, Ksenia V. Zornikova,
- 636 Yana Serdyuk, Dmitry Zubkov, Andrei Afanasiev, Tao Zhu, Luis Barreto.

637 Funding and role of study sponsor

- 638 The study was designed, funded, and managed by NPO Petrovax Pharm LLC (Moscow, Russian
- 639 Federation). NPO Petrovax Pharm LLC in partnership with CanSino Biologics, Inc. (Tianjin, China)

- are funding and managing the clinical development of the Ad5-nCoV vaccine in the Russian
- 641 Federation.

642 **Conflicts of interest/competing interests**

- All authors have read the journal's policy and the authors of this manuscript have the following
- 644 competing interests:. MT, MK, DZ, AA, NK, AT and VD are employees of NPO Petrovax Pharm
- 645 LLC. TZ and LB are employees of CanSino Biologics, Inc. IA, SS, KZ and YS have received
- 646 funding from NPO Petrovax Pharm LLC for consultation services. DL and GE have received
- 647 personal fees from NPO Petrovax Pharm LLC for consultation services.

648 Availability of data and material

649 The authors confirm that the data supporting the findings of this study are available within the article.

650 Transparency declaration

- 651 The corresponding author and guarantor (Vitalina Dzutseva) affirms that this manuscript is an
- honest, accurate, and transparent account of the study being reported; that no important aspects of the
- study have been omitted; and that any discrepancies from the study as planned have been explained.

654 **REFERENCES**

Martini M, Gazzaniga V, Bragazzi NL, Bardberis I. The Spanish Influenza Pandemic: a
lesson from history 100 years after 1918. J Prev Med Hyg. 2019;60(1):E64-E67. doi: 10.15167/24214248/jpmh2019.60.1.1205.

658 2. Nussbaumer-Streit B, Mayr V, Dobrescu AI, Chapman A, Persad E, Klerings I, et al.

659 Quarantine alone or in combination with other public health measures to control COVID-19: a rapid

660 review. Cochrane Database Syst Rev. 2020;4(4):CD013574. doi: 10.1002/14651858.Cd013574.

3. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and

Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:

663 10.1056/NEJMoa2034577.

4. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and
efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of
four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99111. doi: 10.1016/S0140-6736(20)32661-1.

6685.Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety

of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020;384(5):403-416. doi:

670 10.1056/NEJMoa2035389.

671 6. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV,

Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous

673 prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies

674 from Russia. Lancet. 2020;396(10255):887-897. doi:10.1016/s0140-6736(20)31866-3.

675 7. Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Res.

676 2020;288:198114. doi: 10.1016/j.virusres.2020.198114.

- 8. Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, et al. Potent neutralization of
- 678 severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks
- receptor association. Proc Natl Acad Sci U S A. 2004;101:2536-2541.
- 680 9. Zhu F, Guan X, Li Y, Huang J, Jiang T, Hou L, et al. Immunogenicity and safety of a
- recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older:
- a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396: 479–488. doi:
- 683 10.1016/S0140-6736(20)31605-6.
- 684 10. Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and

685 immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,

open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845-1854. doi:

687 10.1016/S0140-6736(20)31208-3.

688 11. Food and Drug Administration (FDA). Center for Biologics Evaluation and Research.

689 Development and Licensure of Vaccines to Prevent COVID-19. 2020. Available from:

- 690 https://www.fda.gov/media/139638/download
- 691 12. European Medicines Agency (EMA). Guideline on clinical evaluation of vaccines. 2018.
- 692 Available from: https://www.who.int/publications/i/item/an-international-randomised-trial-of-
- 693 candidate-vaccines-against-covid-19
- Rules for Conducting Studies of Biological Medicinal Products of the Eurasian Economic
 Union. 2016. Available from: https://docs.eaeunion.org/docs/ru-ru/01411954/cncd_21112016_89

- 696 14. Guidelines for Conducting Clinical Studies of Medicinal Products (Immunobiologicals).
- 697 Part two. 2012: 212. Available from: https://www.thelancet.com/action/showPdf?pii=S0140-
- 698 6736%2820%2931605-6
- 699 15. Clinicaltrials.gov. Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus
- 700 Type 5 Vector) Against COVID-19. 2020. Available from:
- 701 https://clinicaltrials.gov/ct2/show/NCT04540419?term=prometheus&cond=Covid19&cntry=RU&dr
- 702 aw=2&rank=1
- 16. Shomuradova AS, Vagida MS, Sheetikov SA, Zornikova KV, Kiryukhin D, Titov A, et al.
- 704 SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell
- 705 Receptors. Immunity. 2020;53(6):1245-1257.e5. doi: 10.1016/j.immuni.2020.11.004.
- 17. Yu B, Zhou Y, Wu H, Wang Z, Zhan Y, Feng X, et al. Seroprevalence of neutralizing
- antibodies to human adenovirus type 5 in healthy adults in China. J Med Virol. 2012;84(9):1408-
- 708 1414. doi: 10.1002/jmv.23325.
- 18. Pilankatta R, Chawla T, Khanna N, Swaminathan S. The prevalence of antibodies to
- adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines.
- 711 J Med Virol. 2010;82(3):407-414. doi: 10.1002/jmv.21721.
- 712 19. Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, et al. International
- seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.
- 714 Vaccine. 2011;29(32):5203-5209. doi: 10.1016/j.vaccine.2011.05.025.
- 715 20. Tan Y. Covid: what do we know about China's coronavirus vaccines? News: BBC. 2021.
- 716 Available from: https://www.bbc.co.uk/news/world-asia-china-55212787

- 717 21. Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet.
- 718 2021;397(10275):642-643. doi: 10.1016/S0140-6736(21)00191-4.
- 719 22. Sadoff J, Le Gars M, Shukarev, Heerwegh D, Truyers C, de Groot AM, et al. Interim
- 720 Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. New Engl J Med.
- 721 2021;384(19):1824-1835. doi: 10.1056/NEJMoa2034201.
- 722 23. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological
- assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200-1204. doi:
- 724 10.1038/s41591-020-0965-6.
- 725 24. Mancini DP, Kuchler H, Pilling D, Cookson C, Cotterill J. Oxford/AstraZeneca jab fails to
- prevent mild and moderate Covid from S African strain, study shows. Financial Times. 2021.
- 727 Available from: https://www.ft.com/content/e9bbd4fe-e6bf-4383-bfd3-be64140a3f36

783 - Screened 500 - Randomised

374 - Allocated to receive Ad5-nCoV 126 - Allocated to receive Placebo 1 - Withdrawal of informed consent 2 - Screening failure (randomised by mistake) 1 - Screening failure (randomised by mistake) 372 - FAS for safety 124 - FAS for safety analysis analysis 372 - Received Ad5-nCoV 124 - Received placebo 1 - Violation of selection criteria 371 - FAS for immunogenicity analysis 124 - FAS for immunogenicity analysis 3 - Registered COVID-19 cases before Day 14 1 - Prohibited therapy 1 - Registered COVID-19 asymptomatic case 11 - Visit 4 (out of window) 8 - Visit 4 (out of window) 22 - Visit 5 (out of window) 14 - Visit 5 (out of window) 2 - No initial primary immunogenicity variables 6 - Data missing from Visits 4, 5 and post-8 - Data missing from Visits 4, 5 and postvaccination vaccination 324 - PPS for immunogenicity analysis 95 - PPS for immunogenicity analysis 1 - Violation of selection criteria 1 - Registered COVID-19 asymptomatic case 3 - Registered COVID-19 cases before Day 14 3 - Data missing post-vaccination 5 - Data missing post-vaccination 363 - FAS for efficacy analysis 120 - FAS for efficacy analysis 1 - Prohibited therapy 1 - Unblinded with AE

361 - PPS for efficacy analysis

120 - PPS for efficacy analysis











